Regenxbio tumbles as FDA halts rare‑disease gene therapy trials after tumor case
28/01/2026 12:49
** Shares of therapy developer Regenxbio RGNX.O fall 34% to $8.82 premarket ** Co says FDA paused studies of its experimental treatments for two rare childhood disorders ** The two disorders are Hurler syndrome and Hunter syndrome, conditions that cause severe physical and cognitive decline, per co ** Co says a brain tumor was found in a child who received RGX‑111 four years earlier ** Early tests linked therapy DNA near a cancer‑related gene, but causality is unclear, says co ** Co says no similar cases seen in other children treated with RGX‑111 or RGX‑121 ** RGX‑111 and RGX‑121 are experimental gene therapies that co is developing for two rare childhood genetic disorders ** Shares up ~86% in 2025 (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))